NovoCure (NVCR) Enterprise Value (2014 - 2026)

NovoCure (NVCR) has reported Enterprise Value for 13 consecutive years, with -$440.6 million the latest figure, recorded in Q2 2026.

• Quarterly Enterprise Value rose 51.67% year-over-year to -$440.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$440.6 million (up 51.67% YoY) and the FY2025 annual result came in at -$447.7 million, up 53.36% from the prior year.
• Enterprise Value slipped to -$440.6 million in Q2 2026 per NVCR's latest filing, from -$432.0 million in the prior quarter.
• Over the last five years, Enterprise Value for NVCR reached as high as -$432.0 million in Q1 2026 and fell as low as -$1.0 billion in Q3 2025.
• A 5-year average of -$860.4 million and a median of -$936.6 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value declined 7.86% — and 2026, when it soared 53.5%.
• Year by year, Enterprise Value stood at -$969.4 million in 2022, then rose by 6.07% to -$910.6 million in 2023, then retreated by 5.41% to -$959.9 million in 2024, then surged by 53.36% to -$447.7 million in 2025, then advanced by 1.59% to -$440.6 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$440.6 million, -$432.0 million, and -$447.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.